Solid Tumor Clinical Trial
Official title:
A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors
The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | September 30, 2021 |
Est. primary completion date | May 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent. 2. 18-70years old, male or female. 3. Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer(NSCLC) or other solid tumor, previous treated with standard therapy , or standard therapy not suitabl ,or without standard therapy. 4. At least one measurable disease according to RECIST v1.1. 5. Life expectancy of at least 3 months. 6. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. 7. Demonstrate adequate organ function - Exclusion Criteria: 1. uncontrolled primary CNS tumors, brain metastases, or meningeal metastases. 2. Evidence of a tumor that compresses or invades major blood vessels. 3. History of hemoptysis (>1/2 teaspoon per event) or severe bleeding or evidence of bleeding disorders in the last 3 months. 4. Clinically significant active cardiovascular disease within 6 months prior to planned start of PEG-ENDO. 5. Prior treatment with anti-agiogenetic agent. 6. Pregnant female patients; breastfeeding female patients. - |
Country | Name | City | State |
---|---|---|---|
China | Beijing Hospital | Beijing | Beijing |
China | Tianjin medical university cancer institute&hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Simcere Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Limiting Toxicities (DLT) | Incidence of Dose Limiting Toxicity | First 21days for dosing(Cycle1,each cycle is 21 days) | |
Primary | Adverse Event(AE) | Incidence of Adverse Events | From the time the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment | |
Primary | Serious Adverse Event(SAE) | Incidence of Serious Adverse Events | From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment | |
Primary | Laborarory test abnormality | Incidence of clinically significant laboratory abnormalities | From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment | |
Primary | Vital signs abnormality | Incidence of vital signs abnormalities | From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment | |
Primary | Electrocardiogram(ECG) abnormality | Incidence of clinically significant ECG abnormalities | From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment | |
Primary | Serum concentration | Serum concentration of PEG-ENDO | Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles. | |
Primary | The maximum (or peak) serum ,Cmax | Cmax of PEG-ENDO following dose concentration. | Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles. | |
Primary | AUC | The area under the plot of serum concentration of drug (not logarithm of the concentration) against time after drug administration. | Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles. | |
Primary | other PK parameters | The other PK parameters (if applicable). | Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles. | |
Primary | Maximum Tolerated Dose(MTD) | To determine the Maximum Tolerated Dose (MTD) of PEG-ENDO in subjects with Advanced / Metastatic NSCLC or Other Solid Tumors | First 21days for dosing(Cycle1,each cycle is 21 days) | |
Secondary | Overall Response Rate(ORR) | ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) | at least 12 weeks | |
Secondary | Duration of Response(DOR) | DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1 | Estimated at 4 months after fist documented PD or CR | |
Secondary | Progression-free survival (PFS) | PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by by Investigator assessment in accordance to RECIST 1.1 | Estimated at 4 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |